MedPath

Emerging Role of GLP-1 Agonists in Obesity

GLP-1 agonists, initially developed for type 2 diabetes treatment, have shown significant efficacy in promoting weight loss in both preclinical and clinical studies. This review highlights the role of GLP-1 agonists in weight management, their pleiotropic effects, and their impact on hyperglycemia, insulin sensitivity, blood pressure, and cardio-metabolic and renal protection.

Introduction

Obesity is a chronic disease with a high prevalence and associated comorbidities, making it a growing global concern. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss.

Prevalence of Obesity Globally

Obesity is defined by a body mass index (BMI) of 30 kg/m2 or higher. The World Health Organization (WHO) reports that almost 60% of European adults are overweight or obese, with higher prevalence levels among men than women. Obesity is linked to increased mortality rates and is predicted to overtake smoking as the leading preventable risk factor for cancer in some countries.

Complications of Obesity

Obesity-related complications include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others. These conditions have a negative impact on health and increase morbidity and mortality.

The Emergence of GLP-1 Receptor Agonists

GLP-1 receptor agonists (GLP1-RAs) have emerged as a promising treatment for obesity. These medications promote satiety, decrease hunger, and ultimately reduce food intake. They also improve glycemic control, induce weight loss, and offer cardio-metabolic and renal protection.

Liraglutide

Liraglutide, a daily injectable GLP-1 RA, has been shown to significantly reduce body weight in both diabetic and non-diabetic individuals. Clinical trials have demonstrated its efficacy in improving glycemic control and reducing cardiovascular risk factors.

Semaglutide

Semaglutide, another GLP-1 RA, has been extensively studied for its weight loss effects. Clinical trials have shown that semaglutide leads to significant and long-lasting weight loss, with improvements in cardiometabolic risk factors.

Tirzepatide

Tirzepatide, a dual agonist of GIP and GLP-1 receptors, has shown superior efficacy in improving glycemic control and inducing weight loss compared to other GLP-1 drugs. It represents a new vista for the treatment of obese individuals.

Lixisenatide and Exenatide

Lixisenatide and exenatide are other GLP-1 RAs that have been evaluated for their efficacy in weight management and glycemic control. These medications have shown significant reductions in body weight and improvements in glycemic control in clinical trials.

Conclusion

GLP-1 agonists have demonstrated significant efficacy in promoting weight loss and improving health outcomes in individuals with obesity, both with and without type 2 diabetes. These medications offer a promising approach to the management of obesity and its associated comorbidities.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Retatrutide Shows Promising Weight Loss Results Compared to Other GLP-1 Agonists

A recent study shows retatrutide, an investigational triple agonist, led to a 22.1% weight loss over 48 weeks, surpassing existing GLP-1 drugs.
Tirzepatide, commercially available as Zepbound, demonstrated a 17.8% weight loss over 72 weeks, highlighting its effectiveness in obesity management.

GLP-1 Agonists Show Promise as Potential Drug Therapy for Obstructive Sleep Apnea

GLP-1 agonists, initially for diabetes and obesity, are gaining traction as a potential pharmacological treatment for obstructive sleep apnea (OSA), especially in obese patients.
Eli Lilly's tirzepatide is under FDA review for OSA treatment based on the SURMOUNT-OSA trial, which showed significant reductions in apnea-hypopnea index (AHI) in participants.

GLP-1 Agonists Expedite Preoperative Weight Loss in Obese Hernia Patients

A retrospective study reveals that GLP-1 agonists accelerate preoperative weight loss in obese patients undergoing elective hernia repair.
The study showed GLP-1 agonists significantly reduce the time to surgery compared to lifestyle modifications alone, without increasing postoperative complications.

GLP-1 Agonists Show Promise in Weight Management for Breast Cancer Patients

A retrospective study at Memorial Sloan Kettering Cancer Center found that GLP-1 agonists led to an average weight loss of 5% in breast cancer patients.
Weight loss increased with longer duration of GLP-1 agonist treatment, with patients losing over 6 kg by the end of their treatment.

Real-World Study Uncovers Factors Influencing Long-Term Weight Loss with GLP-1 RAs

A Cleveland Clinic study identifies that the active agent, dosage, treatment indication, and persistence significantly impact long-term weight loss with GLP-1 RAs.
Semaglutide demonstrates a greater average weight reduction compared to liraglutide, with higher doses leading to more significant weight loss.

GLP-1 Receptor Agonists Spearhead Obesity Treatment Advancements

Semaglutide (WEGOVY) marked the resurgence of GLP-1R agonists for obesity treatment, gaining FDA approval in June 2021 and achieving blockbuster status with $7.73 billion in sales by 2023.
Tirzepatide (ZEPBOUND), a GIPR/GLP-1R co-agonist, and setmelanotide (IMCIVREE), an MC4R agonist, have expanded the therapeutic landscape for obesity, addressing different mechanisms of action.

GLP-1 Receptor Agonists Show Promise for Weight Loss in Overweight and Obese Individuals Without Diabetes

A comprehensive study evaluating the benefit-harm balance of GLP-1 receptor agonists (RAs) for weight loss in individuals with overweight and obesity but without diabetes has found that these drugs can offer significant weight loss benefits, especially when aiming for a 10% reduction in body weight. However, the net benefit is highly dependent on individual treatment goals and tolerance for potential harms.

Semaglutide Shows Sustained Benefits in Blood Sugar Control and Weight Loss Over Three Years

A recent study presented at the EASD demonstrates that semaglutide significantly improves blood sugar control and promotes weight loss over a three-year period.
The research, involving over 23,000 patients, showed a reduction in HbA1c levels and an average weight loss of 4.7 kilograms after six months of semaglutide treatment.

GLP-1 Agonists Gain Traction in Cardiology for Weight Loss and CV Risk Reduction

GLP-1 receptor agonists like semaglutide are gaining popularity for weight loss and improving cardiometabolic risk factors in patients with obesity or overweight.
Clinical trials such as SELECT and SURMOUNT MMO are investigating the cardiovascular benefits of GLP-1 agonists and tirzepatide in diverse patient populations.

GLP-1 Receptor Agonists Show Significant Weight Loss Benefits in Overweight and Obese Patients

A comprehensive meta-analysis reveals that GLP-1 receptor agonists, particularly semaglutide and liraglutide, significantly contribute to weight loss in overweight or obese individuals, with or without type 2 diabetes mellitus (T2DM). The study highlights the efficacy of these medications in achieving ≥5% or ≥10% weight loss, with semaglutide SQ 2.4mg showing the highest effectiveness. Nausea was associated with greater weight loss, indicating its role as a clinical indicator of treatment efficacy.

Reference News

[1]
Emerging Role of GLP-1 Agonists in Obesity
pmc.ncbi.nlm.nih.gov · Jun 21, 2023

GLP-1 agonists, including liraglutide, semaglutide, and tirzepatide, effectively promote weight loss and improve hypergl...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy